Secondary Hyperparathyroidism in HIV-Infected Patients in Central Europe

Abstract

Secondary hyperparathyroidism (sHPT) might be a contributor to increased risk of osteoporosis in adult HIV patients but there is little data available on this issue in this particular population. The aim of the study was to investigate the prevalence of sHPT in an HIV-infected population with normal kidney function and to evaluate its risk factors in HIV patients. This cross-sectional study was carried out in a single HIV center in Germany using routine data from patients with normal kidney function attending the clinic between January 1st and December 31st, 2016. In total, 1263 patients were included [998 (79.0%) male, median age 48 (IQR 38–54) years]. In 214 patients (16.9%) elevated PTH levels with low or normal calcium levels were found. Multivariate logistic regression modeling showed significant associations with elevated PTH for African ethnicity [OR: 2.12 (95% CI: 1.42–3.16); p<0.001], low 25-hydroxyvitamin D levels [OR: 1.82 (95% CI: 1.32–2.51); p<0.001], low calcium levels [OR 1.69 (95% CI: 1.22–2.33); p=0.001], and use of tenofovir disoproxil fumarate [OR 2.33 (95% CI: 1.62–3.36); p<0.001]. Additional to common risk factors like vitamin D insufficiency and hypocalcemia, we found a significant association between the use of TDF and sHPT. Prospective data are needed to ascertain whether PTH-mediated bone loss is the underlying mechanism of TDF bone-toxicity. Additional screening of PTH even in HIV-infected patients with normal or low calcium levels may help to identify patients at increased risk of bone mineral density loss.

Key words

parathyroid hormone - tenofovir - calcium - vitamin D

• References

• 1 Bandeira L, Bilezikian J. Primary Hyperparathyroidism. F1000Res 2016; 5 pii: F1000 Faculty Rev-1.
• 2 Fraser WD. Hyperparathyroidism. Lancet 2009; 374: 145-158
• 3 Prince RL. Secondary and tertiary hyperparathyroidism. In: Favus MJ. (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. 6th ed. Washington DC: American Society for Bone and Mineral Research; 2006: 191
• 4 Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001; 22: 477-501
• 5 Potts JT. Parathyroid hormone: past and present. J Endocrinol 2005; 187: 311-325
• 6 Patricio Jr. JA, Lopes PF, Medeiros T, Mendes GF, Silva AA, Esberard EB, Lugon JR, Almeida JR. Tenofovir monotherapy for hepatitis B after 1 year does not produce renal dysfunction, but is associated with hyperparathyroidism not related to vitamin D. Eur J Gastroenterol Hepatol 2016; 28: 64-69
• 7 Aziz N, Butch AW, Quint JJ, Detels R. Association of Blood Biomarkers of Bone Turnover in HIV-1 Infected Individuals Receiving Anti-Retroviral Therapy (ART). J AIDS Clin Res 2014; 5: 360
• 8 Lerma E, Molas ME, Montero MM, Guelar A, Gonzalez A, Villar J, Diez A, Knobel H. Prevalence and factors associated with vitamin D deficiency and hyperparathyroidism in HIV-infected patients treated in barcelona. Isrn Aids 2012; 485307
• 9 Rosenvinge MM, Gedela K, Copas AJ, Wilkinson A, Sheehy CA, Bano G, Hay PE, Pakianathan MR, Sadiq ST. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr 2010; 54: 496-499
• 10 Pocaterra D, Carenzi L, Ricci E, Minisci D, Schiavini M, Meraviglia P, Bevilacqua M, Zucchi P, Bonfanti P, Rizzardini G. Secondary hyperparathyroidism in HIV patients: Is there any responsibility of highly active antiretroviral therapy?. Aids 2011; 25: 1430-1433
• 11 Hoy J, Young B. Do people with HIV infection have a higher risk of fracture compared with those without HIV infection?. Curr Opin HIV Aids 2016; 11: 301-305
• 12 Cortes YI, Yin MT, Reame NK. Bone density and fractures in hiv-infected postmenopausal women: A systematic review. J Assoc Nurses AIDS Care 2015; 26: 387-398
• 13 Hileman CO, Eckard AR, McComsey GA. Bone loss in HIV: A contemporary review. Curr Opin Endocrinol Diabetes Obes 2015; 22: 446-451
• 14 Casado JL, Banon S, Andres R, Perez-Elias MJ, Moreno A, Moreno S. Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients. Osteoporos Int 2014; 25: 1071-1079
• 15 Das S, Bopitya S, Taha H, David L. Relationship between vitamin D, parathyroid hormone, bone mineral density, fracture and antiretroviral therapy in HIV patients. Recent Pat Antiinfect Drug Discov 2014; 9: 6-13
• 16 Hosmer DW, Lemeshow S, Sturdivant RX. Model-Building Strategies and Methods for Logistic Regression. In Applied Logistic Regression. 3rd ed. 2013: 89-151
• 17 Payne RB. LA Williams RB, Milner JR. Interpretation of serum calcium levels in patients with abnormal serum proteins. Br Med J 1973; 4: 643-646
• 18 von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 2007; 370: 1453-1457
• 19 Silver J, Kilav R, Naveh-Many T. Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2002; 283: F367-F376
• 20 Boonen S, Bischoff-Ferrari HA, Cooper C, Lips P, Ljunggren O, Meunier PJ, Reginster JY. Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: A review of the evidence. Calcif Tissue Int 2006; 78: 257-270
• 21 Sudjaritruk T, Bunupuradah T, Aurpibul L, Kosalaraksa P, Kurniati N, Prasitsuebsai W, Sophonphan J, Ananworanich J, Puthanakit T. Hypovitaminosis D and hyperparathyroidism: Effects on bone turnover and bone mineral density among perinatally HIV-infected adolescents. Aids 2016; 30: 1059-1067
• 22 Laroche M, Nigon D, Gennero I, Lassoued S, Pouilles JM, Tremolieres F, Vallet M, Tack I. [Vitamin D deficiency prediction by patient questionnaire and secondary hyperparathyroidism in a cohort of 526 healthy subjects in their fifties]. Presse Med 2015; 44: e283-e290
• 23 Moslehi N, Shab-Bidar S, Mirmiran P, Hosseinpanah F, Azizi F. Determinants of parathyroid hormone response to vitamin D supplementation: A systematic review and meta-analysis of randomised controlled trials. Br J Nutr 2015; 114: 1360-1374
• 24 Das S, Bopitya S, Chowdhury AR, Das A, Taha H. Effect of Low Dose Oral Vitamin-D and Calcium Replacement in HIV Patients. Recent Pat Antiinfect Drug Discov 2016; 11: 59-67
• 25 Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Mulligan K. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: A randomized, placebo-controlled trial. Clin Infect Dis 2012; 54: 1013-1025
• 26 O'Connor MY, Thoreson CK, Ramsey NL, Ricks M, Sumner AE. The uncertain significance of low vitamin D levels in African descent populations: a review of the bone and cardiometabolic literature. Prog Cardiovasc Dis 2013; 56: 261-269
• 27 Samarawickrama A, Jose S, Sabin C, Walker-Bone K, Fisher M, Gilleece Y. No association between vitamin D deficiency and parathyroid hormone, bone density and bone turnover in a large cohort of HIV-infected men on tenofovir. J Int AIDS Soc 2014; 17: 19568
• 28 Cotter AG, Vrouenraets SM, Brady JJ, Wit FW, Fux CA, Furrer H, Brinkman K, Sabin CA, Reiss P, Mallon PW. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. J Clin Endocrinol Metab 2013; 98: 1659-1666
• 29 Hamzah L, Tiraboschi JM, Iveson H, Toby M, Mant C, Cason J, Burling K, Wandolo E, Jendrulek I, Taylor C, Ibrahim F, Kulasegaram R, Teague A, Post FA, Fox J. Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: A randomized, controlled trial (MIDAS). Antivir Ther 2016; 21: 287-296
• 30 Klassen KM, Kimlin MG, Fairley CK, Emery S, Anderson PH, Ebeling PR. Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV. Osteoporos Int 2016; 27: 1737-1745
• 31 Bonnet E, Ruidavets JB, Genoux A, Mabile L, Busato F, Obadia M, Prevoteau F, Marchou B, Massip P, Marion-Latard F, Delpierre C, Bernard J, Perret B. Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: The prospective Lipotrip study. BMC Infect Dis 2013; 13: 293
• 32 Dave JA, Cohen K, Micklesfield LK, Maartens G, Levitt NS. Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans. PLoS One 2015; 10: e0144286
• 33 Bouvier G. Protease inhibitors can interfere with vitamin D metabolism. HIV Clin 2009; 21: 9-10
• 34 Cervero M, Agud JL, Garcia-Lacalle C, Alcazar V, Torres R, Jusdado JJ, Moreno Guillen S. Prevalence of vitamin D deficiency and its related risk factor in a Spanish cohort of adult HIV-infected patients: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2012; 28: 963-971
• 35 Cervero M, Agud JL, Torres R, Garcia-Lacalle C, Alcazar V, Jusdado JJ, Moreno S. Higher vitamin D levels in HIV-infected out-patients on treatment with boosted protease inhibitor monotherapy. HIV Med 2013; 14: 556-562
• 36 Tinago W, Cotter AG, Sabin CA, Macken A, Kavanagh E, Brady JJ, McCarthy G, Compston J, Mallon PW. Predictors of longitudinal change in bone mineral density in a cohort of HIV-positive and negative patients. Aids 2017; 31: 643-652
• 37 Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, Avihingsanon A, Crofoot G, Benson P, Lichtenstein K, Ramgopal M, Chetchotisakd P, Custodio JM, Abram ME, Wei X, Cheng A, McCallister S, SenGupta D, Fordyce MW. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr 2016; 71: 530-537
• 38 Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong L, Callebaut C, Das M, Fordyce M. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr 2016; 72: 58-64
• 39 Mills A, Crofoot Jr. G, McDonald C, Shalit P, Flamm JA, Gathe Jr. J, Scribner A, Shamblaw D, Saag M, Cao H, Martin H, Das M, Thomas A, Liu HC, Yan M, Callebaut C, Custodio J, Cheng A, McCallister S. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: A randomized phase 2 study. J Acquir Immune Defic Syndr 2015; 69: 439-445
• 40 Bech A, Van Bentum P, Telting D, Gisolf J, Richter C, De Boer H. Treatment of calcium and vitamin D deficiency in HIV-positive men on tenofovir-containing antiretroviral therapy. HIV. Clin Trials 2012; 13: 350-356
• 41 Nordenstrom E, Katzman P, Bergenfelz A. Biochemical diagnosis of primary hyperparathyroidism: Analysis of the sensitivity of total and ionized calcium in combination with PTH. Clin Biochem 2011; 44: 849-852